Ferriprox

Drug - Ferriprox (deferiprone) [ApoPharma USA, Inc.]

February 2012

Therapeutic area - Iron Chelator

Approval for use

• Patient has transfusional iron overload due to thalassemia syndromes AND
• Patient has tried and failed deferoxamine or defarasirox
• Special care parameters with Ferriprox use in patients with renal or hepatic impairment are in place (verbal affirmation by physician, pharmacist or nurse is acceptable)

Background information

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval was based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival.

Limitation of use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias. No specific studies have been conducted to evaluate its safety and efficacy in patients with renal or hepatic impairment. 

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411